Latest Breaking News On - Arsenic trioxide based first line therapy - Page 1 : comparemela.com

BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD New post-hoc analysis.

Mont saint guibertWaals gewestFrance generalSeitosei actifinGhislaine gasparettoNeil hunter michelle boxallNeither the companyInternational media enquiriesIb communicationsEuronext brusselsChronic graft versus host diseaseArsenic trioxideCellular therapyHigh response rateArsenic trioxide based first line therapyAllogeneic hematopoietic stem cell